

Company registration number: 457338

Specialist Medical Services Locums Limited
Unaudited abridged financial statements
for the financial period ended 31 March 2025

Specialist Medical Services Locums Limited

Contents

	Page
Directors and other information	1
Directors responsibilities statement	2
Balance sheet	3
Notes to the financial statements	4 - 6

Specialist Medical Services Locums Limited

Directors and other information

Directors	André Nel Denize Tait (Retired 23 September 2024) Leslie Byrne (Retired 23 September 2024)
Secretary	Denize Tait
Company number	457338
Registered office	1st Floor Medical Suite Link Road Holywell Road Swords Co Dublin
Accountants	John McEvoy + Co High Street Trim Co Meath C15 FX38
Bankers	Bank of Ireland University Branch Montrose Dublin 4

Specialist Medical Services Locums Limited

Directors responsibilities statement

These abridged financial statements have been extracted, pursuant to section 353 of the Companies Act 2014, from the statutory financial statements prepared under section 290 of that Act. The following is the Directors Responsibilities Statement accompanying those financial statements.

The directors are responsible for preparing the directors report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial period. Under the law, the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 105 "The Financial Reporting Standard applicable to the Micro-entities regime" issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial period end date and of the profit or loss of the company for the financial period and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgments and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and directors report comply with the Companies Act 2014. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Specialist Medical Services Locums Limited

Balance sheet As at 31 March 2025

	31/03/25	30/06/24
	€	€
Fixed assets	734,498	768,941
Current assets	43,070	45,488
Creditors: amounts falling due within one year	(1,510,039)	(1,326,009)
Net current liabilities	(1,466,969)	(1,280,521)
Total assets less current liabilities	(732,471)	(511,580)
Creditors: amounts falling due after more than one year	(315,604)	(395,668)
Accruals and deferred income	(7,000)	(7,000)
Net liabilities	(1,055,075)	(914,248)
Capital and reserves	(1,055,075)	(914,248)

We, as directors of Specialist Medical Services Locums Limited state that:

- (a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014;
- (b) the company is availing itself of the exemption on the grounds that the conditions specified in section 358 of the Companies Act 2014 are satisfied;
- (c) the shareholders of the company have not served a notice on the company under section 334(1) of the Companies Act 2014 in accordance with section 334(2);
- (d) we acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial period and of its profit or loss for such a financial period and to otherwise comply with the provisions of Companies Act 2014 relating to financial statements so far as they are applicable to the company; and
- (e) the company has relied on the specified exemption contained in section 352 of the Companies Act 2014; has done so on the grounds that the company is entitled to the benefit of that exemption as a micro company and the abridged financial statements have been properly prepared in accordance with section 353 of the Companies Act 2014.

The financial statements have been prepared in accordance with the micro companies regime.

These abridged financial statements were approved by the board of directors on 20 February 2026 and signed on behalf of the board by:

André Nel
Director

Specialist Medical Services Locums Limited

Notes to the abridged financial statements Financial period ended 31 March 2025

1. General information

The company is a private company limited by shares, registered in the Republic of Ireland. The address of the registered office is 1st Floor Medical Suite, Link Road, Holywell Road, Swords, Co Dublin. The company has changed its reporting date to 31 March (previously 30 June). These are the first financial statements that reflect the new reporting date. These accounts cover the 9 month period from 1 July 2024 to 31 March 2025.

2. Statement of compliance

These financial statements have been prepared in accordance with FRS 105, 'The Financial Reporting Standard applicable to the Micro-entities Regime'.

3. Accounting policies and measurement bases

Basis of preparation

The financial statements have been prepared on the historical cost basis.

The financial statements are prepared in Euro, which is the functional currency of the entity.

Turnover

Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer, usually on despatch of the goods; the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity and the costs incurred or to be incurred in respect of the transactions can be measured reliably.

Tangible assets

Tangible assets are measured initially at cost, and are subsequently stated at cost less accumulated depreciation and impairment losses.

Depreciation

Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:

If there is an indication that there has been a significant change in depreciation rate, useful life or residual value of tangible assets, the depreciation is revised prospectively to reflect the new estimates.

Financial assets

Financial assets are measured initially at cost, and subsequently stated at cost less accumulated impairment losses.

Specialist Medical Services Locums Limited

Notes to the abridged financial statements (continued) Financial period ended 31 March 2025

Financial instruments

A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument.

Financial instruments are initially recognised at cost, which is the transaction price.

Investments in shares, subsidiaries or participating interests are subsequently measured at cost less impairment.

Derivatives are subsequently measured at the cost plus any transaction costs not immediately recognised in profit or loss less any impairment losses recognised to date. This is allocated to profit or loss over the term of the contract on a straight-line basis, unless another systematic basis of allocation is more appropriate.

Other financial instruments are subsequently measured at the cost plus any transaction costs not immediately recognised in profit or loss, plus accumulated interest income or expense recognised to date, less all repayments of principal or interest to date, less impairment.

Financial assets are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately.

Any reversals of impairment are recognised in profit or loss immediately.

Defined contribution plans

Contributions to defined contribution plans are recognised as an expense in the period in which the related service is provided. Prepaid contributions are recognised as an asset to the extent that the prepayment will lead to a reduction in future payments or a cash refund.

When contributions are not expected to be settled wholly within 12 months of the end of the reporting date in which the employees render the related service, the liability is measured on a discounted present value basis. The unwinding of the discount is recognised in finance costs in profit or loss in the period in which it arises.

4. Appropriations of profit and loss account

	31/03/25	30/06/24
	€	€
At the start of the financial period	(914,250)	(712,854)
Loss for the financial period	(140,827)	(201,396)
At the end of the financial period	(1,055,077)	(914,250)

Specialist Medical Services Locums Limited

**Notes to the abridged financial statements (continued)
Financial period ended 31 March 2025**

5. Directors transactions

During the financial period the company entered into the following arrangements relating to loans, quasi-loans and credit transactions:

	31/03/25	30/06/24
	€	€
At the start of the financial period	10,893	10,893
Advances made during the financial period	4,989	-
At the end of the financial period	<u>15,882</u>	<u>10,893</u>

Disclosure for each director or other person is as follows:

André Nel

	31/03/25	30/06/24
	€	€
At the start of the financial period	10,893	10,893
Advances made during the financial period	4,989	-
At the end of the financial period	<u>15,882</u>	<u>10,893</u>

	31/03/25	30/06/24
	€	€
Maximum amount outstanding	<u>15,882</u>	<u>10,893</u>